Action(s) taken or orders passed

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 25th June 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sir, Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the captioned subject, we would like to inform you that the Company has received a Demand Notice dated 24th June 2026 from the National Pharmaceutical Pricing Authority. The relevant details to be disclosed are as under: Sr no Particulars Details 1 Name of the authority National Pharmaceutical Pricing Authority 2 Nature and details of the action(s) taken, initiated Demand Notice dated 24th June 2026 or order(s) passed Total Demand Rs. 3,54,12,025/- (Alleged overcharging-Rs.1,22,91,163;Interest–2,31,20,862) 3 Date of receipt of direction or order, including any 24th June 2026 ad-interim or interim orders, or any other communication from the authority 4 Details of violation(s) / contravention(s) committed Overcharged in the sale of scheduled formulations or alleged to be committed by charging price higher than the price fixed / notified by the Government / NPPA in the relevant period. 5 Impact on financial, operation or other activities of No impact on financial operations of the Company. the listed entity, quantifiable in monetary terms to The Company would be filing an appeal against the extent possible demand order. Kindly take the same on the record. Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary CIN: L24239MH1924PLC001151